SCHEMBL2942800

SCHEMBL2942800

COc1nccc2oc(C(=O)Nc3ccc(Cl)cn3)c(NC(=O)C3CCC(N4CCOCC4=O)CC3)c12

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 9/20 0.41
▸ NPY5R Q15761 5/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MAPK1 P28482 2/20 0.36
▸ RAB9A P51151 1/20 0.35
▸ F2 P00734 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942799 1.00 F10 (0.41) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL2944237 0.93 F10 (0.39) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL2944239 0.93 F10 (0.39) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL2950657 0.91 F10 (0.42) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL2950659 0.91 F10 (0.42) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL2951708 0.91 F10 (0.41) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL2951709 0.91 F10 (0.41) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL13290689 0.90 NPY5R (0.47) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL13290880 0.90 F10 (0.41) F10NPY5RSMN1; SMN2MAPK1RAB9A
SCHEMBL13290736 0.89 F10 (0.44) F10NPY5RSMN1; SMN2MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US claimed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US claimed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP claimed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 F10 4/4885NPY5R 805/4885SMN1; SMN2 4447/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 F10 4/4885NPY5R 589/4885SMN1; SMN2 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback